Monitoring and Evaluation of Therapy Response in Advanced-Stage Lung Cancer Treated with Systemic Therapy
Downloads
Lung cancer is the second most commonly diagnosed malignancy, with the highest mortality rate in the world. In Indonesia, lung cancer ranks third with 34,783 cases, contributing to the highest number of deaths due to cancer. Most patients are diagnosed at an advanced stage, requiring systemic therapy. Therapeutic modalities for lung cancer patients can include surgery, radiotherapy, and systemic therapy, with the choice of therapy determined by the histological type, disease stage, laboratory results, performance status (PS), and comorbidities. This situation requires regular monitoring and evaluation to reduce the symptoms and improve the patient’s quality of life (QoL). Therapy response in systemic therapy patients can be evaluated through subjective, semi-subjective, and objective evaluations. Subjective evaluation involves monitoring QoL, focusing on cancer outcomes, and patients’ well-being. Semi-subjective evaluation consists of monitoring the patient’s weight and PS. Objective evaluation uses imaging equipment, such as computed tomography (CT) scans, fluoroscopy, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans to monitor tumor progression.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209–249. [PubMed]
Kementerian Kesehatan Republik Indonesia. Hari Kanker Sedunia 2019. Kemenkes, https://kemkes.go.id/id/hari-kanker-sedunia-2019 (2019).
Duma N, Santana-Davila R, Molina J. Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc 2019; 94: 1623–1640. [PubMed]
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC). Philadelphia, https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450 (2023).
American Society of Clinical Oncology. ASCO Cancer Treatment and Survivorship Care Plans, https://www.cancer.org/cancer/survivorship/long-term-health-concerns/survivorship-care-plans.html (2021).
Miller M, Hanna N. Advances in Systemic Therapy for Non-Small Cell Lung Cancer. BMJ 2021; 375: n2363. [PubMed]
Broaddus VC, Ernst JD, King TE, et al. Murray & Nadel’s Textbook of Respiratory Medicine E-Book. Elsevier, https://books.google.co.id/books?id=R5UwEAAAQBAJ (2021).
Araghi M, Mannani R, Maleki AH, et al. Recent Advances in Non-Small Cell Lung Cancer Targeted Therapy; An Update Review. Cancer Cell Int 2023; 23: 162. [PubMed]
Dingemans AMC, Früh M, Ardizzoni A, et al. Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol Off J Eur Soc Med Oncol 2021; 32: 839–853. [PubMed]
Hendriks LE, Kerr KM, Menis J, et al. Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. Ann Oncol Off J Eur Soc Med Oncol 2023; 34: 339–357. [PubMed]
Kementerian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/1438/2023 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Paru. HK.01.07/MENKES/1438/2023, Indonesia, https://kemkes.go.id/app_asset/file_content_download/16998444836551918303c728.14190138.pdf (2023).
Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022; 20: 497–530. [PubMed]
Jusuf A, Wibawanto A, Icksan A, et al. Kanker Paru. Jakarta, 2015.
Marhana IA, Amin M, Permatasari A, et al. Buku Ajar Paru 2022. Surabaya: Airlangga University Press, https://books.google.co.id/books?id=tG6dEAAAQBAJ (2022).
Di Maio M, Basch E, Denis F, et al. The Role of Patient-Reported Outcome Measures in the Continuum of cancer Clinical Care: ESMO Clinical Practice Guideline. Ann Oncol Off J Eur Soc Med Oncol 2022; 33: 878–892. [PubMed]
Lehto RH. Psychosocial Challenges for Patients with Advanced Lung Cancer: Interventions to Improve Well-Being. Lung Cancer (Auckland, NZ) 2017; 8: 79–90. [PubMed]
Prapa P, Papathanasiou IV, Bakalis V, et al. Quality of Life and Psychological Distress of Lung Cancer Patients Undergoing Chemotherapy. World J Oncol 2021; 12: 61–66. [PubMed]
Iyer S, Roughley A, Rider A, et al. The Symptom Burden of Non-Small Cell Lung Cancer in the USA: A Real-World Cross-Sectional Study. Support Care Cancer Oofficial J Multinatl Assoc Support Care Cancer 2014; 22: 181–187. [PubMed]
Reenen M van, Janssen B, Stolk E, et al. EQ-5D-5L User Guide. Rotterdam, https://euroqol.org/wp-content/uploads/2023/11/EQ-5D-5LUserguide-23-07.pdf (2019).
Mohindra NA, Peipert JD, Blum SI, et al. General Population Reference Values for the Functional Assessment of Cancer Therapy-Lung and PROMIS-29. Cancer Med 2023; 12: 12765–12776. [PubMed]
DeVita VT, DeVita VT, Rosenberg SA, et al. Devita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. Wolters Kluwer, https://books.google.co.id/books?id=3ih5zgEACAAJ (2023).
Lin T, Yang J, Hong X, et al. Nutritional Status in Patients with Advanced Lung Cancer Undergoing Chemotherapy: A Prospective Observational Study. Nutr Cancer 2020; 72: 1225–1230. [PubMed]
Gul B, Metintas S, Ak G, et al. The Relationship between Nutritional Status and Prognosis in Patients with Locally Advanced and Advanced Stage Lung Cancer. Support Care Cancer 2021; 29: 3357–3365. [PubMed]
Jain R, Coss C, Whooley P, et al. The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer. Curr Oncol Rep 2020; 22: 54. [PubMed]
Azam F, Latif MF, Farooq A, et al. Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals. Case Rep Oncol 2019; 12: 728–736. [PubMed]
Wilson BE, Wright K, Koven R, et al. Surveillance Imaging after Curative-Intent Treatment for Cancer: Benefits, Harms, and Evidence. J Clin Oncol 2024; 42: 2245–2249. [PubMed]
Edelman MJ, Meyers FJ, Siegel D. The Utility of Follow-Up Testing after Curative Cancer Therapy. A Critical Review and Economic Analysis. J Gen Intern Med 1997; 12: 318–331. [PubMed]
Planchard D, Popat S, Kerr K, et al. Metastatic Non-Small Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol Off J Eur Soc Med Oncol 2018; 29: iv192–iv237. [PubMed]
Munzenrider JE. Handbook of Cancer Diagnosis and Treatment Evaluation. Int J Radiat Oncol Biol Phys 2009; 75: 1621. [Journal]
Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). Eur J Cancer 2009; 45: 228–247. [PubMed]
Volpi S, Ali JM, Tasker A, et al. The Role of Positron Emission Tomography in the Diagnosis, Staging and Response Assessment of Non-Small Cell Lung Cancer. Ann Transl Med 2018; 6: 95. [PubMed]
Hwang KE, Kim HR. Response Evaluation of Chemotherapy for Lung Cancer. Tuberc Respir Dis (Seoul) 2017; 80: 136–142. [PubMed]
Sheikhbahaei S, Mena E, Yanamadala A, et al. The Value of FDG PET/CT in Treatment Response Assessment, Follow-Up, and Surveillance of Lung Cancer. AJR Am J Roentgenol 2017; 208: 420–433.[PubMed]
Seymour L, Bogaerts J, Perrone A, et al. iRECIST: Guidelines for Response Criteria for Use in Trials Testing Immunotherapeutics. Lancet Oncol 2017; 18: e143–e152. [PubMed]
Ma Y, Wang Q, Dong Q, et al. How to Differentiate Pseudoprogression from True Progression in Cancer Patients Treated with Immunotherapy. Am J Cancer Res 2019; 9: 1546–1553. [PubMed]
Bustoros M, Mouhieddine TH, Detappe A, et al. Established and Novel Prognostic Biomarkers in Multiple Myeloma. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet 2017; 37: 548–560. [PubMed]
Jiang C, Zhao M, Hou S, et al. The Indicative Value of Serum Tumor Markers for Metastasis and Stage of Non-Small Cell Lung Cancer. Cancers (Basel); 14. Epub ahead of print October 2022. [PubMed]
Oya Y, Yoshida T, Kuroda H, et al. Association between EGFR T790M Status and Progression Patterns during Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation. Clin Lung Cancer 2017; 18: 698-705.e2. [PubMed]
Copyright (c) 2025 Ibrahim Syamsuri, Anna Febriani, Laksmi Wulandari, Farah Fatma Wati

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.